Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 1
1968 1
1969 8
1970 6
1971 2
1972 2
1973 2
1974 3
1975 1
1976 1
1977 1
1978 2
1979 3
1980 5
1981 6
1982 10
1983 10
1984 12
1985 10
1986 13
1987 18
1988 13
1989 10
1990 10
1991 5
1992 6
1993 11
1994 7
1995 8
1996 12
1997 11
1998 7
1999 10
2000 11
2001 8
2002 18
2003 20
2004 22
2005 27
2006 39
2007 30
2008 44
2009 31
2010 40
2011 42
2012 53
2013 49
2014 47
2015 35
2016 39
2017 38
2018 31
2019 37
2020 43
2021 51
2022 44
Text availability
Article attribute
Article type
Publication date

Search Results

937 results
Results by year
Filters applied: . Clear all
Page 1
Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA).
Hamanishi J, Takeshima N, Katsumata N, Ushijima K, Kimura T, Takeuchi S, Matsumoto K, Ito K, Mandai M, Nakai H, Sakuragi N, Watari H, Takahashi N, Kato H, Hasegawa K, Yonemori K, Mizuno M, Takehara K, Niikura H, Sawasaki T, Nakao S, Saito T, Enomoto T, Nagase S, Suzuki N, Matsumoto T, Kondo E, Sonoda K, Aihara S, Aoki Y, Okamoto A, Takano H, Kobayashi H, Kato H, Terai Y, Takazawa A, Takahashi Y, Namba Y, Aoki D, Fujiwara K, Sugiyama T, Konishi I. Hamanishi J, et al. Among authors: nagase s. J Clin Oncol. 2021 Nov 20;39(33):3671-3681. doi: 10.1200/JCO.21.00334. Epub 2021 Sep 2. J Clin Oncol. 2021. PMID: 34473544 Clinical Trial.
Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.
Seto T, Kato T, Nishio M, Goto K, Atagi S, Hosomi Y, Yamamoto N, Hida T, Maemondo M, Nakagawa K, Nagase S, Okamoto I, Yamanaka T, Tajima K, Harada R, Fukuoka M, Yamamoto N. Seto T, et al. Among authors: nagase s. Lancet Oncol. 2014 Oct;15(11):1236-44. doi: 10.1016/S1470-2045(14)70381-X. Epub 2014 Aug 27. Lancet Oncol. 2014. PMID: 25175099 Clinical Trial.
Efficacy and safety of standard of care with/without bevacizumab for platinum-resistant ovarian/fallopian tube/peritoneal cancer previously treated with bevacizumab: The Japanese Gynecologic Oncology Group study JGOG3023.
Shoji T, Enomoto T, Abe M, Okamoto A, Nagasawa T, Oishi T, Nagase S, Mori M, Inokuchi Y, Kamiura S, Komiyama S, Takeshima N, Sugiyama T. Shoji T, et al. Among authors: nagase s. Cancer Sci. 2022 Jan;113(1):240-250. doi: 10.1111/cas.15185. Epub 2021 Nov 18. Cancer Sci. 2022. PMID: 34716979 Free PMC article. Clinical Trial.
Time for enhancing government-led primary prevention of cervical cancer.
Min KJ, Suh DH, Baba T, Chen X, Kim JW, Kobayashi Y, Kwon J, Lim MC, Lee JY, Nagase S, Park JY, Tangjitgamol S, Watari H. Min KJ, et al. Among authors: nagase s. J Gynecol Oncol. 2021 Jan;32(1):e12. doi: 10.3802/jgo.2021.32.e12. Epub 2020 Dec 11. J Gynecol Oncol. 2021. PMID: 33327045 Free PMC article. No abstract available.
Recent advances in claudin-targeting technology.
Nagase S, Doyama R, Yagi K, Kondoh M. Nagase S, et al. Biol Pharm Bull. 2013;36(5):708-14. doi: 10.1248/bpb.b13-00014. Biol Pharm Bull. 2013. PMID: 23649330 Free article. Review.
Clinical statistics of gynecologic cancers in Japan.
Yamagami W, Nagase S, Takahashi F, Ino K, Hachisuga T, Aoki D, Katabuchi H. Yamagami W, et al. Among authors: nagase s. J Gynecol Oncol. 2017 Mar;28(2):e32. doi: 10.3802/jgo.2017.28.e32. Epub 2017 Feb 10. J Gynecol Oncol. 2017. PMID: 28198168 Free PMC article. Review.
Functionally validated SCN5A variants allow interpretation of pathogenicity and prediction of lethal events in Brugada syndrome.
Ishikawa T, Kimoto H, Mishima H, Yamagata K, Ogata S, Aizawa Y, Hayashi K, Morita H, Nakajima T, Nakano Y, Nagase S, Murakoshi N, Kowase S, Ohkubo K, Aiba T, Morimoto S, Ohno S, Kamakura S, Nogami A, Takagi M, Karakachoff M, Dina C, Schott JJ, Yoshiura KI, Horie M, Shimizu W, Nishimura K, Kusano K, Makita N. Ishikawa T, et al. Among authors: nagase s. Eur Heart J. 2021 Jul 31;42(29):2854-2863. doi: 10.1093/eurheartj/ehab254. Eur Heart J. 2021. PMID: 34219138
937 results